81924 Federal Register / Vol. 85, No. 243 / Thursday, December 17, 2020 / Notices 

1See 12 CFR 217.402, 217.404. 

2Method 2 uses similar inputs to those used in 

Method 1, but replaces the substitutability category 

with a measure of a firm’s use of short-term 

wholesale funding. In addition, Method 2 is 

calibrated differently from Method 1. 

3The data used by the Board are available on the 

BCBS website at https://www.bis.org/bcbs/gsib/ 

denominators/gsib_framework_denominators_

end19_exercise.xlsx. 4 12 CFR 217.404(b)(1)(i)(B); 80 FR 49082, 49086– 

87 (August 14, 2015). In addition, the Board 

maintains the GSIB Framework Denominators on its 

website, available at https://

www.federalreserve.gov/bankinforeg/basel/ 

denominators.htm. 

5 Data are provided by the BCBS (as published by 

the European Central Bank, available at http://

www.ecb.europa.eu/stats/eurofxref/index.en.html). 

Supervision and Regulation; or Mark 

Buresh, Senior Counsel, (202) 452–5270, 

or Mary Watkins, Counsel, (202) 452– 

3722, Legal Division. Board of 

Governors of the Federal Reserve 

System, 20th and C Streets NW, 

Washington, DC 20551. For users of 

Telecommunications Device for the Deaf 

(TDD) contact (202) 263–4869. 

SUPPLEMENTARY INFORMATION: The 

Board’s GSIB surcharge rule establishes 

a methodology to identify global 

systemically important bank holding 

companies in the United States (GSIBs) 

based on indicators that are correlated 

with systemic importance.1 Under the 

GSIB surcharge rule, a firm must 

calculate its GSIB score using a specific 

formula (Method 1). Method 1 uses five 

equally weighted categories that are 

correlated with systemic importance— 

size, interconnectedness, crossjurisdictional activity, substitutability, 

and complexity—and subdivided into 

twelve systemic indicators. A firm 

divides its own measure of each 

systemic indicator by an aggregate 

global indicator amount. A firm’s 

Method 1 score is the sum of its 

weighted systemic indicator scores 

expressed in basis points. The GSIB 

surcharge for a firm is the higher of the 

GSIB surcharge determined under 

Method 1 and a second method, Method 

2, which weights size, 

interconnectedness, cross-jurisdictional 

activity, complexity, and a measure of a 

firm’s reliance on short-term wholesale 

funding.2

The aggregate global indicator 

amounts used in the score calculation 

under Method 1 are based on data 

collected by the Basel Committee on 

Banking Supervision (BCBS). The BCBS 

amounts are determined based on the 

sum of the systemic indicator amounts 

as reported by the 75 largest U.S. and 

foreign banking organizations as 

measured by the BCBS, and any other 

banking organization that the BCBS 

includes in its sample total for that year. 

The BCBS publicly releases these 

amounts, denominated in euros, each 

year.3 Pursuant to the GSIB surcharge 

rule, the Board publishes the aggregate 

global indicator amounts each year as 

denominated in U.S. dollars using the 

euro-dollar exchange rate provided by 

the BCBS.4 Specifically, to determine 

the 2020 aggregate global indicator 

amounts, the Board multiplied each of 

the euro-denominated indicator 

amounts made publicly available by the 

BCBS by 1.1234, which was the daily 

euro to U.S. dollar spot rate on 

December 31, 2019.5

The aggregate global indicator 

amounts for purposes of the 2020 

Method 1 score calculation under 

§ 217.404(b)(1)(i)(B) of the GSIB 

surcharge rule are: 

AGGREGATE GLOBAL INDICATOR AMOUNTS IN U.S. DOLLARS (USD) FOR 2020 

Category Systemic indicator 

Aggregate global 

indicator amount 

(in USD) 

Size ................................................... Total exposures ........................................................................................... 91,356,116,001,552 

Interconnectedness ........................... Intra-financial system assets ....................................................................... 8,711,746,598,677 

Intra-financial system liabilities .................................................................... 9,745,958,746,356 

Securities outstanding .................................................................................. 16,507,336,812,775 

Substitutability ................................... Payments activity ......................................................................................... 2,597,250,324,410,487 

Assets under custody .................................................................................. 181,254,610,899,160 

Underwritten transactions in debt and equity markets ................................ 7,280,431,346,279 

Complexity ........................................ Notional amount of over-the-counter (OTC) derivatives ............................. 623,682,857,713,896 

Trading and available-for-sale (AFS) securities .......................................... 3,854,344,460,622 

Level 3 assets .............................................................................................. 577,982,516,649 

Cross-jurisdictional activity ................ Cross-jurisdictional claims ........................................................................... 22,968,366,792,194 

Cross-jurisdictional liabilities ........................................................................ 18,594,151,540,975 

Authority: 12 U.S.C. 248(a), 321–338a, 

481–486, 1462a, 1467a, 1818, 1828, 1831n, 

1831o, 1831p–l, 1831w, 1835, 1844(b), 1851, 

3904, 3906–3909, 4808, 5365, 5368, 5371. 

By order of the Board of Governors of the 

Federal Reserve System, acting through the 

Director of Supervision and Regulation under 

delegated authority. 

Ann Misback, 

Secretary of the Board. 

[FR Doc. 2020–27591 Filed 12–16–20; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Community Living 

Agency Information Collection 

Activities; Proposed Collection; Public 

Comment Request; Independent Living 

Services (ILS) Program Performance 

Report (PPR) 0985–0043 

AGENCY: Administration for Community 

Living, HHS. 

ACTION: Notice. 

SUMMARY: The Administration for 

Community Living (ACL) is announcing 

an opportunity for the public to 

comment on the proposed collection of 

information listed above. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal agencies are required to 

publish a notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. This Extension of a Currently 

Approved Collection (ICR Rev) solicits 

comments on the information collection 

requirements related to the Independent 

Living Services (ILS) Program 

Performance Report (PPR). 

DATES: Comments on the collection of 

information must be submitted 

Federal Register / Vol. 85, No. 243 / Thursday, December 17, 2020 / Notices 81925 

electronically by 11:59 p.m. (EST) or 

postmarked by February 16, 2021. 

ADDRESSES: Submit electronic 

comments on the information collection 

request to: Peter Nye at 

OILPPRAComments@acl.hhs.gov. 

Submit written comments on the 

collection of information to 

Administration for Community Living, 

Washington, DC 20201, Attention: Peter 

Nye. 

FOR FURTHER INFORMATION CONTACT: 

Peter Nye, Administration for 

Community Living, Washington, DC 

20201, (202) 795–7606, or peter.nye@

acl.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ includes 

agency requests or requirements that 

members of the public submit reports, 

keep records, or provide information to 

a third party. Section 3506(c)(2)(A) of 

the PRA (44 U.S.C. 3506(c)(2)(A)) 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, ACL is 

publishing a notice of the proposed 

collection of information set forth in 

this document. 

With respect to the following 

collection of information, ACL invites 

comments on our burden estimates or 

any other aspect of this collection of 

information, including: 

(1) Whether the proposed collection 

of information is necessary for the 

proper performance of ACL’s functions, 

including whether the information will 

have practical utility; 

(2) the accuracy of ACL’s estimate of 

the burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used 

to determine burden estimates; 

(3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and 

(4) ways to minimize the burden of 

the collection of information on 

respondents, including through the use 

of automated collection techniques 

when appropriate, and other forms of 

information technology. 

The Independent Living Services 

(ILS) program provides financial 

assistance, through formula grants, to 

states, the District of Columbia, Puerto 

Rico, American Samoa, the 

Commonwealth of the Northern Mariana 

Islands, Guam, and the US Virgin 

Islands for expanding, and improving 

the provision of, independent living (IL) 

services. The Designated State Entity 

(DSE) is the agency that, on behalf of the 

state, receives, accounts for, and 

disburses funds received under Part B of 

the Rehabilitation Act of 1973, as 

amended (the Act). Funds are also made 

available for the provision of training 

and technical assistance to Statewide 

Independent Living Councils (SILCs). 

The Act permits an annual program 

performance report (PPR). This request 

is for the ILS PPR, which is submitted 

annually by the SILC and DSE in every 

state, territory, and commonwealth. 

ACL uses the ILS PPR to assess grantee 

compliance with title VII of the Act, 

with 45 CFR part 1329 of the Code of 

Federal Regulations, and with 

applicable provisions of the HHS 

Regulations at 45 CFR part 75. The ILS 

PPR serves as the primary basis for 

ACL’s monitoring activities in 

fulfillment of its responsibilities under 

sections 706 and 722 of the Act. ACL 

also uses the PPR to identify training 

and technical assistance needs for SILCs 

and centers for independent living. 

To view the data collection activity 

for this information collection request, 

please visit the ACL public input 

website: https://www.acl.gov/about-acl/ 

public-input. 

Estimated Program Burden 

ACL estimates the burden of this 

collection of information as follows: 

Fifty-six jurisdictions—specifically, the 

fifty states, Puerto Rico, the District of 

Columbia, American Samoa, the 

Commonwealth of the Northern Mariana 

Islands, Guam, and the US Virgin 

Islands—will each complete ILS PPRs 

annually, and it will take an estimated 

thirty-five hours per jurisdiction per ILS 

PPR. Each jurisdiction’s SILC and DSE 

will collaborate to complete the ILS 

PPR. The fifty-six jurisdictions, 

combined, will take an estimated 1,960 

hours per year to complete ILS PPRs. 

This burden estimate is based on what 

DSEs and SILCs have told ACL about 

how long filling out ILS PPRs took in 

previous reporting years. 

Respondent/data collection activity Number of 

respondents 

Responses 

per 

respondent 

Hours per 

response 

Total annual 

burden hours 

SILCs and DSEs .............................................................................................. 56 1 35 1,960 

Dated: December 10, 2020. 

Mary Lazare, 

Principal Deputy Administrator. 

[FR Doc. 2020–27734 Filed 12–16–20; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2019–D–3679] 

Interacting With the Food and Drug 

Administration on Complex Innovative 

Trial Designs for Drugs and Biological 

Products; Guidance for Industry; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a final 

guidance entitled ‘‘Interacting with the 

FDA on Complex Innovative Trial 

Designs for Drugs and Biological 

Products.’’ The guidance provides 

recommendations to sponsors and 

applicants on interacting with FDA on 

complex innovative trial design (CID) 

proposals for drugs or biological 

products. FDA is issuing this guidance 

to satisfy, in part, a mandate under the 

21st Century Cures Act (Cures Act). In 

accordance with the Cures Act mandate, 

this guidance discusses the use of novel 

trial designs in the development and 

regulatory review of drugs and 

biological products, how sponsors may 

obtain feedback on technical issues 

related to modeling and simulation, and